Most Hepatotoxic TB Drug
Pyrazinamide is the most hepatotoxic first-line tuberculosis drug, with the CDC and American Thoracic Society explicitly stating it carries the highest risk of severe liver injury among standard TB medications. 1
Evidence Supporting Pyrazinamide as Most Hepatotoxic
The CDC's definitive statement identifies pyrazinamide as the most hepatotoxic among first-line TB agents, which led to major guideline revisions in 2003 when the rifampin-pyrazinamide regimen for latent TB was abandoned due to unacceptably high rates of severe liver injury and death. 1 This represents the strongest guideline-level evidence available.
The combination of rifampin and pyrazinamide demonstrates 3-fold higher hepatotoxicity rates compared to isoniazid monotherapy, with hospitalization rates of 3.0 per 1,000 and death rates of 0.9 per 1,000 treatment initiations. 2
Clinical Patterns of Hepatotoxicity
Two distinct patterns of liver injury occur with TB drugs: 3
- Early hepatotoxicity (within 15 days): Typically caused by rifampin-enhanced isoniazid toxicity, with generally good prognosis 3
- Late hepatotoxicity (>1 month): Associated with pyrazinamide, carrying a poor prognosis and higher risk of fulminant hepatic failure 3
The late-onset pyrazinamide hepatotoxicity pattern is particularly dangerous because it can progress to fulminant liver failure with worse outcomes than early isoniazid-related injury. 3
Comparative Hepatotoxicity Risk
Among the first-line drugs: 4, 3
- Pyrazinamide: Most hepatotoxic, especially when combined with other hepatotoxic agents 1
- Isoniazid: Major hepatotoxin, but less severe than pyrazinamide 3
- Rifampin: Rarely hepatotoxic alone, but enhances isoniazid toxicity through enzyme induction 3
- Ethambutol: Rarely or not hepatotoxic 3
High-Risk Populations Requiring Avoidance
The rifampin-pyrazinamide combination should never be offered to patients with: 1, 2
- Concurrent hepatotoxic medications
- Excessive alcohol consumption
- Underlying liver disease of any etiology
- History of previous drug-induced liver injury, particularly from isoniazid
Management Implications
When pyrazinamide-induced hepatotoxicity occurs, the drug should not be reintroduced due to high recurrence risk and poor prognosis. 3 The sequential reintroduction protocol after drug-induced liver injury specifically adds pyrazinamide last, and only if absolutely necessary, reflecting its higher toxicity profile. 5
If pyrazinamide cannot be tolerated, treatment must be extended to 9 months total with rifampin and isoniazid (plus ethambutol for initial 2 months), compared to the standard 6-month regimen. 5
Monitoring Requirements for Pyrazinamide
When pyrazinamide must be used, intensive monitoring is mandatory: 1
- Baseline liver function tests required
- Monitoring at 2,4,6, and 8 weeks
- Immediate discontinuation if ALT >5× upper limit of normal (asymptomatic) or >3× with symptoms
The hepatotoxicity risk increases when pyrazinamide doses exceed 20 mg/kg/day, making proper weight-based dosing critical. 2